RCKT Stock Cash Flow Statements

Rocket Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Rocket Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31

operating activities:
net income	-68,919,000	-61,334,000	-60,327,000	-66,719,000	-69,646,000	-62,054,000	-59,660,000	-61,899,000	-65,701,000	-58,335,000	-66,723,000	-57,756,000	-54,402,000	-42,982,000	-50,118,000	-34,525,000	-40,179,000	-29,080,000	-25,040,000	-24,664,000	-19,284,000	-18,680,000	-19,451,000	-16,089,000	-15,767,000	-15,343,000	-4,870,000	-7,395,000	-6,562,000	-10,670,000	-12,974,000	-11,128,000	-8,684,000	-10,068,000	-55,961,000	-2,387,000	-1,462,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization of property and equipment	2,040,000	2,451,000	1,822,000	1,851,000	1,832,000	1,716,000	1,396,000	1,221,000	1,192,000	1,135,000	1,049,000	1,085,000	1,031,000	767,000
amortization of finance lease right of use asset	539,000	538,000	539,000	538,000	539,000	538,000	539,000	538,000	539,000	538,000
stock-based compensation	10,857,000	10,331,000	11,088,000	11,248,000	11,332,000	10,252,000	9,930,000	10,316,000	10,245,000	8,915,000	9,693,000	7,677,000	7,369,000	6,270,000	6,989,000	7,311,000	7,900,000	4,047,000	4,489,000	3,961,000							1,548,000	911,000	793,000	784,000	931,000	805,000	687,000	486,000	374,000	194,000	1,364,000
accretion of discount on investments	-2,212,000	-2,075,000		-1,849,000	-2,242,000	-2,754,000						155,000	400,000	577,000	744,000				126,000	-63,000	-332,000	-256,000	-247,000	-366,000
change in fair value of warrant liabilities																																			0	0	-267,000
changes in operating assets and liabilities:
prepaid expenses and other assets	667,000	-467,000	354,000	-286,000	422,000	-1,151,000	4,656,000	-4,660,000	1,832,000	866,000	-2,315,000	-194,000	2,852,000	-3,936,000	-14,000	1,872,000	-842,000	1,107,000	-2,251,000	-271,000	815,000	-2,091,000	-307,000	1,162,000			-185,000	342,000	848,000	-45,000	-608,000	-840,000	448,000	52,000	-394,000	-303,000	-271,000
accounts payable and accrued expenses	8,121,000	-5,258,000	774,000	3,171,000	4,535,000	-2,413,000	15,758,000	-1,134,000	3,273,000	-7,750,000	2,485,000	4,641,000	3,039,000	-491,000	6,140,000	-16,029,000	7,047,000	4,940,000	-1,256,000	-1,932,000	4,243,000	-2,181,000	-84,000	1,479,000	3,524,000	-2,261,000
operating lease liabilities and right of use assets	10,000	12,000	17,000	22,000	37,000	13,000
finance lease liability	13,000	12,000	15,000	24,000	29,000	27,000	30,000	35,000	37,000	37,000	38,000	44,000	45,000	45,000	460,000	1,247,000	-63,000	568,000	846,000	151,000
other liabilities			-1,877,000	-103,000	-661,000	-1,030,000	1,067,000	-203,000	197,000	-720,000	-14,000
net cash from operating activities	-48,964,000	-55,790,000	-46,942,000	-52,103,000	-53,823,000	-56,856,000	-29,339,000	-57,148,000	-50,869,000	-57,560,000	-56,021,000	-43,859,000	-39,039,000	-39,223,000	-27,413,000	-38,526,000	-24,283,000	-17,253,000	-22,033,000	-22,245,000	-10,849,000	-18,104,000	-15,977,000	-11,635,000	-9,738,000	-11,601,000	-2,988,000	-5,585,000	-5,920,000	-11,619,000	-11,138,000	-9,132,000	-8,003,000	-8,993,000	-4,327,000	-4,057,000	-1,993,000
capex	-50,000	-313,000	-389,000	-2,359,000	-1,817,000	-1,112,000	-5,240,000	-4,250,000	-4,648,000	-1,221,000	-3,003,000	839,000	-4,127,000	-320,000	-3,624,000	-186,000	9,000	1,830,000	-746,000	-2,411,000	-3,891,000	-10,221,000	3,632,000	-453,000	-109,000	-8,000	0	0	-17,000	-53,000	0	-108,000	-221,000	-15,000	-288,000	0	0
free cash flows	-49,014,000	-56,103,000	-47,331,000	-54,462,000	-55,640,000	-57,968,000	-34,579,000	-61,398,000	-55,517,000	-58,781,000	-59,024,000	-43,020,000	-43,166,000	-39,543,000	-31,037,000	-38,712,000	-24,274,000	-15,423,000	-22,779,000	-24,656,000	-14,740,000	-28,325,000	-12,345,000	-12,088,000	-9,847,000	-11,609,000	-2,988,000	-5,585,000	-5,937,000	-11,672,000	-11,138,000	-9,240,000	-8,224,000	-9,008,000	-4,615,000	-4,057,000	-1,993,000
investing activities:
purchases of investments	-52,689,000	-139,931,000	-124,045,000	-19,320,000	-38,574,000	-63,947,000	-208,502,000	-13,488,000	-72,896,000	-96,034,000	-198,867,000	-34,437,000	0	-143,023,000	-67,913,000	-54,756,000	-103,815,000	-75,665,000	-32,955,000	-23,481,000	-9,910,000			-22,268,000
proceeds from maturities of investments	84,500,000	82,260,000	86,483,000	99,827,000	96,128,000	101,016,000	72,344,000	66,397,000	108,250,000	62,335,000	50,820,000	58,405,000	81,686,000	81,983,000	53,562,000	105,615,000	74,969,000	15,397,000	31,909,000	56,805,000	51,800,000	20,001,000	29,935,000	20,023,000
purchases of property and equipment	-50,000	-364,000	-309,000	-1,588,000	-1,930,000	-2,035,000	-4,647,000	-4,655,000	-4,119,000	-3,015,000	-3,003,000	-503,000	-2,897,000	-1,955,000	-3,458,000	-1,121,000	-328,000	161,000	-1,908,000	-5,207,000	-6,710,000	-6,545,000	-760,000	-453,000	-109,000	-8,000		0	-17,000	-53,000		-108,000	-221,000	-15,000
net cash from investing activities	31,761,000	-58,035,000		78,919,000	55,624,000	35,034,000	-140,805,000	48,254,000	31,206,000	-36,721,000	-108,585,000	23,465,000	78,789,000	-62,995,000	-18,189,000	49,352,000	-29,174,000	-64,193,000	-5,435,000	27,499,000	35,180,000	-126,880,000	29,175,000	-2,985,000	-107,414,000	86,078,000	32,562,000	27,137,000	8,222,000	7,094,000	-42,281,000	4,931,000	-16,366,000	-12,343,000
financing activities:
issuance of common stock, pursuant to exercise of stock options			321,000	176,000	1,530,000	1,184,000	390,000	545,000	182,000	1,114,000	323,000	229,000	3,000	76,000	284,000	1,115,000	8,792,000
return of related party short-swing profits
net cash from financing activities			182,849,000	176,000	1,530,000	1,184,000	391,000	189,485,000	182,000	18,343,000	108,440,000	29,526,000	17,246,000	76,000	26,638,000	1,115,000	8,792,000	512,000	151,000	-117,000	31,000			149,000	0	78,518,000		-16,000				48,686,000
net change in cash, cash equivalents and restricted cash	-16,988,000	-113,825,000	98,036,000	26,992,000	3,331,000	-20,638,000	-169,753,000	180,591,000	-19,481,000	-75,938,000	-56,166,000	9,132,000	56,996,000	-102,142,000	-18,964,000	11,941,000	-44,665,000	-80,934,000	-27,317,000	5,137,000	24,362,000	-59,631,000	13,198,000	-14,471,000
cash, cash equivalents and restricted cash at beginning of period	0	164,997,000	0	0	0	57,276,000	0	0	0	141,857,000	0	0	0	234,037,000	0	0	298,666,000	0	0	186,908,000	0	0	112,791,000	0	0	18,349,000
cash, cash equivalents and restricted cash at end of period	-16,988,000	51,172,000	98,036,000	26,992,000	3,331,000	36,638,000	-169,753,000	180,591,000	-19,481,000	65,919,000	-56,166,000	9,132,000	56,996,000	131,895,000	-18,964,000	11,941,000	254,001,000	-80,934,000	-27,317,000	192,045,000	24,362,000	-59,631,000	125,989,000	-14,471,000	-117,152,000	171,344,000
supplemental disclosure of non-cash financing and investing activities:
accrued purchases of property and equipment, ending balance		51,000	-80,000	-771,000	113,000	923,000	-593,000	405,000	-529,000	1,794,000
investment maturity receivables and purchase payables, ending balance					-576,000	8,648,000
operating lease liabilities			0	0	0	1,134,000	2,809,000	18,000	5,000	97,000	-24,000	-32,000	-31,000	-33,000	-33,000	65,000	-15,000	-20,000	358,000	-452,000	-22,000	170,000	-210,000
operating lease right of use assets
net unrealized loss on investments	-80,000	-93,000
impairment of acquired intangible asset							0
write down of property and equipment							20,000				59,000	0	137,000	40,000				0	-1,000	63,000
accretion of discount and amortization of premium on investments
cash proceeds from acquisition of business, net of cash paid
payments made to acquire right of use asset							0	0	-29,000	-7,000					43,000			-3,808,000	-2,201,000	-530,000
net cash provided by/(used in) investing activities
issuance of common stock, net of issuance costs							1,000											587,000
treasury stock repurchase
issuance of common stock, pursuant to sale of treasury stock							0
issuance of common stock, pursuant to the at-the-market offering program, net of issuance costs							0
issuance of common stock, pursuant to exercise of warrants							0
receivables from sale of property and equipment, ending balance
unrealized gain on investments						-454,000				267,000					-16,000			-160,000	304,000	-95,000	-27,000	233,000	38,000
issuance of common stock related to acquisition
reclassification of construction in process from finance right of use asset
unrealized loss on investments				431,000				214,000			239,000	169,000	-136,000	-468,000			-33,000
accretion of discount on convertible notes															47,000	116,000	589,000	669,000	572,000	844,000	917,000	883,000	850,000	787,000	758,000	696,000
expense in connection with warrant issuance
operating lease liability and right of use asset
conversion of convertible notes into common stock
supplemental cash flow information:
cash paid for interest															-1,199,000	0	1,347,000	1,465,000	0	1,495,000	1,495,000	0	1,495,000	1,495,000	0	1,495,000	0	1,495,000	0	1,462,000					0	0	89,000
amortization of premium and accretion of discount on investments								-2,245,000	-2,488,000	-2,343,000
exercise of warrants									0	7,000
issuance of common stock pursuant to the at-the-market offering program, net of issuance costs									0	17,222,000	26,000	29,297,000
amortization of right of use asset														535,000
amortization of premium on investments
changes in operating assets and liabilities, net of acquisition:
proceeds from sale of treasury stock, net of cash paid
payment of withholding tax on option exercise																		-76,000
convertible notes refinancing costs to the lender																		0	-139,000	-98,000
finance lease right of use asset and lease liability																		0	0	20,179,000
right of use asset												535,000
accrued purchases of property and equipment												1,342,000	-1,230,000	1,635,000	-166,000	935,000	337,000	1,669,000	1,162,000	2,796,000	2,819,000	-3,676,000	4,392,000
unrealized loss on marketable securities
other long term liabilities													-14,000	-15,000	-13,000	-15,000	-14,000
reclassification of construction in process to finance right of use asset																	325,000
depreciation and amortization expense															808,000	706,000	674,000	273,000
purchases of internal use software															-423,000			-278,000	-280,000	-88,000
common stock repurchase																		0	0	-72,000	0
proceeds from sale of treasury stock																		0	538,000	53,000
proceeds from exercise of options
payment of withholding tax on option exercises
accrued purchases of internal use software															-96,000	-189,000	311,000	-22,000	-52,000	174,000
conversion of 2021 and 2022 convertible notes into common stock
reclassification of construction in process (from) to finance right of use asset
accretion of discount (amortization of premium) on investments																	620,000
retirement of treasury stock																				72,000	-2,000	0	1,395,000
witholding tax payable on shares witheld in treasury stock																				429,000
net exercise of options																					0
reclassification of construction in process of finance right of use asset																		0	0	26,465,000
increase in lease liability
depreciation expense																				118,000	121,000	102,000	102,000	76,000	74,000	83,000
stock-based compensation expense																					2,693,000
loss on disposal of property and equipment																								107,000
cash acquired in connection with the reverse merger																								0	0	76,348,000
proceeds from sale of property and equipment																								0	0	20,000
payment of security deposit
proceeds from issuance of common stock, net of issuance costs																					0			0	0	78,518,000
conversion of convertible preferred stock into common stock																								0	0	41,466,000
cash paid for income taxes
amortization of operating lease right-of-use assets																							190,000
share-based compensation expense																							3,180,000	2,612,000	2,786,000	5,382,000
amortization of premium on short term investments																										12,000
(increase in) / reduction of lease liability																								-71,000
accrued research and development costs																								-1,332,000	-714,000	116,000
proceeds from issuance of convertible preferred stock
supplemental disclosure of non-cash financing activities:
reduction of lease liability																										-20,000
prepaid expenses																										-266,000
proceeds from maturities of short term investments																										9,718,000
net change in cash and restricted cash																										152,995,000
cash flows from operating activities:
adjustments to reconcile net income to cash from operating activities:
noncash interest expense																											151,000	148,000	143,000	139,000	140,000				555,000	303,000	274,000
noncash rent																											-14,000
noncash asset impairment charge																											14,000
amortization of premium on marketable securities																											33,000	51,000	62,000	71,000	61,000	52,000	69,000	43,000
depreciation																											38,000	38,000	63,000	61,000	58,000	39,000	35,000	37,000	6,000
accounts payable																											68,000	15,000	-1,534,000	310,000	-185,000	856,000	-455,000	-257,000	896,000	-487,000	154,000
accrued expenses and other liabilities																											229,000
cash flows from investing activities:
purchases of short-term investments																											0	0	-14,482,000	-12,722,000	-53,207,000	-11,656,000	-33,253,000	-24,161,000
proceeds from the maturities of short-term investments																											32,562,000	27,137,000	22,721,000	19,869,000	11,069,000	16,695,000	17,108,000	11,833,000
purchase of property and equipment																																			-288,000
cash flows from financing activities:
proceeds from issuance of 2021 convertible notes																															0
payments of 2021 convertible notes issuance costs																															0
net proceeds from issuance of common stock																															0	-52,000
proceeds from the issuance of common stock pursuant to stock option plans
proceeds from the issuance of common stock pursuant to employee stock purchase plan
payments made for taxes of employees who surrendered shares related to settlement of restricted stock
net cash from financing activities:																																				-40,000	51,514,000
net change in cash and cash equivalents																											29,574,000	21,536,000	2,337,000	-4,525,000	-53,206,000	44,485,000	-20,187,000	-21,336,000	40,236,000	-4,127,000	49,521,000
cash and cash equivalents, beginning of period																											0	0	0	29,798,000	0	0	0	80,042,000	0	0	3,618,000
cash and cash equivalents, end of period																											29,574,000	21,536,000	2,337,000	25,273,000	-53,206,000	44,485,000	-20,187,000	58,706,000	40,236,000	-4,127,000	53,139,000
supplemental disclosure of cash flow information:
supplemental disclosure of noncash investing and financing activities:
net unrealized gain on marketable securities																											9,000	47,000	0	-18,000		-15,000	17,000	11,000
proceeds from issuance of common stock pursuant to stock option plans																																0
proceeds from issuance of common stock pursuant to employee stock purchase plan																												0				0
payments made for taxes of employees who surrendered shares related to unrestricted stock
noncash rent expense																													-15,000	-15,000	-14,000
accrued expenses and other current liabilities																													282,000	-2,254,000	1,453,000	1,017,000	-88,000	730,000	-164,000	481,000	170,000
loss on extinguishment of debt																																			3,717,000	0	522,000
change in fair value of convertible bridge notes redemption rights derivative																																			0	0	-480,000
change in fair value of 2020 convertible notes derivative liability																																			46,649,000
net proceeds from issuance of common stock in initial public offering
proceeds from issuance of 2020 convertible notes in initial public offering																																					21,000,000
payments of 2020 convertible notes issuance costs																																			0	0	-1,841,000
proceeds from the issuance of common stock pursuant to stock option plan
principal payments on notes payable																																			0
acquisition of leasehold improvements
conversion of series aa preferred stock into common stock upon initial public offering																																			0	0	46,383,000
conversion of series x preferred stock into common stock upon initial public offering																																			0	0	548,000
conversion of convertible bridge notes into common stock upon initial public offering																																			0	0	2,028,000
conversion of 2020 convertible notes into common stock
accretion of series aa preferred stock to redemption value																																			0	0	130,000
reclassification of fair value of warrant liability to equity upon initial public offering																																			0	0	215,000
reclassification of deferred public offering costs to stockholders’ equity																																			0
reclassification of deferred public offering costs to other assets																																			0	0	256,000
net unrealized loss on marketable securities
reclassification of deferred public offering costs to stockholders' equity
deferred rent and lease incentives																																	-15,000	-16,000
purchase of short-term investments
proceeds from issuance of common stock in initial public offering, net of issuance costs																																			-30,000	-40,000	38,155,000
proceeds from issuance of common stock in follow-on public offering, net of issuance costs
proceeds from exercise of stock options
proceeds from exercise of warrants for series aa preferred stock
accrual of series aa preferred stock dividends
reclassification of fair value of warrant liability related to exercise of preferred stock warrants
net cash from investing activities:
proceeds from issuance of 2020 convertible notes in initial public offering, net of underwriting discounts
change in fair value of 2020 convertible notes derivative																																					-1,997,000
principal and termination payments on notes payable																																					-5,800,000
reclassification of deferred public offering costs to stockholders’s equity																																					1,590,000
adjustments to reconcile net income to cash used by operating activities:
change in fair value of warrant liabilities and convertible notes redemption rights derivative
net proceeds from issuance of notes payable and series aa preferred stock warrants
net proceeds from issuance of convertible notes
net proceeds from issuance of series aa preferred stock and series aa preferred stock warrants
issuance of 2,677,731 shares of series aa preferred stock upon conversion of convertible notes and accrued interest
conversion of series aa preferred stock to common stock

We provide you with 20 years of cash flow statements for Rocket Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rocket Pharmaceuticals stock. Explore the full financial landscape of Rocket Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Rocket Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.